



IPW

ATTORNEY'S DOCKET NUMBER: 2004117-0024 (NEMC 284 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: D. Bianchi *et al.* **Examiner:** NYA
Serial No.: 10/577,341 **Group Art Unit:** NYA
Filing Date: April 28, 2006
Corresp. to: PCT/US2004/035929 **International Filing Date:** October 29, 2004
Earliest Priority: 60/515,735 **Filing Date:** October 30, 2003
Title: Prenatal Diagnosis Using Cell-Free Fetal DNA in Amniotic Fluid

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER


Enclosed are the following documents:

1. Form PTO-1449 (9 pages);
2. Information Disclosure Statement (6 pages);
3. Cited Art (87); and
4. Return Postcard.


If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721

Respectfully submitted,

Dated: May 7, 2007


C. Hunter Baker, M.D., Ph.D.
Registration Number: 46,533

CHOATE, HALL & STEWART LLP
Patent Department
Two International Place
Boston, MA 02110
Tel: 617-248-5000
Fax: 617-248-4000


Certificate of Mailing	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
May 7, 2007	
Date	Signature
	Beatrice M. Aveline, Ph.D.
Typed or Printed Name of person signing certificate	



ATTORNEY'S DOCKET NUMBER: 2004117-0024 (NEMC 284 US)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: D. Bianchi *et al.* **Examiner:** NYA
Serial No.: 10/577,341 **Group Art Unit:** NYA
Filing Date: April 28, 2006
Corresp. to: PCT/US2004/035929 **International Filing Date:** October 29, 2004
Earliest Priority: 60/515,735 **Filing Date:** October 30, 2003
Title: Prenatal Diagnosis Using Cell-Free Fetal DNA in Amniotic Fluid

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postag as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
May 7, 2007 Date	 Signature
Beatrice M. Aveline, Ph.D. Typed or Printed Name of person signing certificate	

Sir:

**STATEMENT FILED PURSUANT TO THE
DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- [X] An *original* Information Disclosure Statement; or
[] A *supplemental* Information Disclosure Statement.

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☒ Before the mailing of a first Office action on the merits; or
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- ☐ Certifies that *either*:
 - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p).

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ [X] A copy of each cited reference not indicated with a * is included;
- ☐ [] Copies of references indicated with a † on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided/cited to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:
- ☐ [] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ [X] Does not contain non-English language citations;
- ☐ [] Does contain non-English language citations, of which an English language translation of the Abstract for each is provided herein:
- ☐ [] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: 5/7, 2007



C. Hunter Baker, M.D., Ph.D.
Registration Number: 46,533

CHOATE, HALL & STEWART, LLP
PATENT GROUP
Two International Place
Boston, MA 02110
Tel: 617-248-5000
Fax: 617-248-4000

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant:
Bianchi, *et al.*Filing Date:
April 28, 2006Group:
TBA

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	* 4,355,153	Radici et al.	October 19, 1982	528	191
	* 4,458,066	Caruthers et al.	July 3, 1984	536	25.34
	* 4,652,613	Collins et al.	March 24, 1987	525	69
	* 4,683,195	Mullis et al.	July 28, 1987	435	6
	* 4,683,202	Mullis	July 28, 1987	435	91.2
	* 4,774,339	Haugland et al.	September 27, 1988	548	405
	* 4,800,159	Mullis et al.	January 24, 1989	435	91.2
	* 5,047,519	Hobbs et al.	September 10, 1991	536	27.14
	* 5,068,269	Diamantoglou	November 26, 1991	524	35
	* 5,143,854	Pirrung et al.	September 1, 1992	436	518
	* 5,151,507	Hobbs et al.	September 29, 1992	536	26.7
	* 5,187,288	Kang et al.	February 16, 1993	548	110
	* 5,227,487	Haugland et al.	July 13, 1993	546	15
	* 5,248,782	Haugland et al.	September 28, 1993	548	110
	* 5,266,489	Rey-Senelongue et al.	November 30, 1993	435	320.1
	* 5,286,486	Payne et al.	February 15, 1994	424	93.2
	* 5,288,625	Hadlaczky	February 22, 1994	435	449
	* 5,288,641	Roizman	February 22, 1994	435	320.1
	* 5,434,049	Okano et al.	July 18, 1995	435	6
	* 5,501,979	Geller et al.	March 26, 1996	435	320.1
	* 5,539,517	Cabib et al.	July 23, 1996	356	456
	* 5,556,752	Lockhart et al.	September 17, 1996	435	6
	* 5,614,386	Metzker et al.	March 25, 1997	435	91.1
	* 5,632,957	Heller et al.	May 27, 1997	422	68.1
	* 5,635,351	Feuerstein et al.	June 3, 1997	435	6
	* 5,665,549	Pinkel et al.	September 9, 1997	435	6
	* 5,700,637	Southern et al.	December 23, 1997	435	6
	* 5,714,386	Roederer	February 3, 1998	436	546
	* 5,721,098	Pinkel et al.	February 24, 1998	435	6

INFORMATION DISCLOSURE STATEMENT*(Use several sheets if necessary)*Applicant:
Bianchi, *et al.*Filing Date:
April 28, 2006Group:
TBA

	* 5,721,118	Scheffler	February 24, 1998	435	69.1
	* 5,744,305	Fodor et al.	April 28, 1998	435	6
	* 5,770,456	Holmes	June 23, 1998	436	518
	* 5,776,745	Ketner et al.	July 7, 1998	435	477
	* 5,790,727	Dhadwal et al.	August 4, 1998	385	38
	* 5,795,557	Pajonk et al.	August 18, 1995	790	727,
	* 5,800,992	Fodor et al.	September 1, 1998	435	6
	* 5,807,522	Brown et al.	September 15, 1998	422	50
	* 5,830,645	Pinkel et al.	November 3, 1998	435	6
	* 5,843,767	Beattie	December 1, 1998	435	287.1
	* 5,846,708	Hollis et al.	December 8, 1998	435	6
	* 5,856,097	Pinkel et al.	January 5, 1999	435	6
	* 5,856,174	Lipshutz et al.	January 5, 1999	435	286.5
	* 5,874,259	Szybalski	February 23, 1999	435	91.1
	* 5,880,473	Ginestet	March 9, 1999	250	458.1
	* 5,922,617	Wang et al.	July 13, 1999	436	518
	* 5,939,261	Loewy et al.	August 17, 1999	435	6
	* 5,943,129	Hoyt et al.	August 24, 1999	356	318
	* 5,959,098	Goldberg et al.	September 28, 1999	536	25.3
	* 5,965,362	Pinkel et al.	October 12, 1999	435	6
	* 5,965,452	Kovacs	October 12, 1999	436	149
	* 5,976,790	Pinkel et al.	November 2, 1999	435	6
	* 5,981,175	Loring et al.	November 9, 1999	435	6
	* 5,994,063	Metzker et al.	November 30, 1999	435	6
	* 6,013,440	Lipshutz et al.	January 11, 2000	435	6
	v6,022,963	McGall et al.	February 8, 2000	536	25.3
	* 6,024,872	Mahendran et al.	February 15, 2000	210	500.25
	* 6,025,155	Hadlaczky et al.	February 15, 2000	435	69.1
	* 6,027,709	Little et al.	February 22, 2000	424	1.65
	* 6,045,996	Cronin et al.	April 4, 2000	435	6
	* 6,048,457	Kopaciewicz et al.	April 11, 2000	210	321.6
	* 6,048,695	Bradley et al.	April 11, 2000	435	6

INFORMATION DISCLOSURE STATEMENT*(Use several sheets if necessary)*Applicant:
Bianchi, *et al.*Filing Date:
April 28, 2006Group:
TBA

	* 6,049,380	Goodwin et al.	April 11, 2000	356	317
	* 6,054,270	Southern	April 25, 2000	435	6
	* 6,054,279	Nadeau et al.	April 25, 2000	435	6
	* 6,055,325	Garini et al.	April 25, 2000	382	129
	* 6,060,324	Naguib	May 9, 2000	436	7
	* 6,063,338	Pham et al.	May 16, 2000	422	61
	* 6,066,459	Garini et al.	May 23, 2000	435	6
	* 6,077,697	Hadlaczky et al.,	June 20, 2000	435	6
	* 6,096,817	Mc Namara	August 1, 2000	524	406
	* 6,140,044	Besemer et al.	October 31, 2000	435	6
	* 6,143,495	Lizardi et al.	November 7, 2000	435	6
	* 6,159,685	Pinkel et al.	December 12, 2000	435	6
	* 6,183,957	Cole et al.	February 6, 2001	435	6
	* 6,191,425	Imai	February 20, 2001	250	458.1
	* 6,197,501	Cremer et al.	March 6, 2001	435	6
	* 6,235,504	Zhang et al.	May 22, 2001	435	91.2
	* 6,252,664	Barbera-Guillem	June 26, 2001	356	417
	* 6,258,606	Kovacs	July 10, 2001	436	149
	* 6,261,776	Pirrung et al.	July 17, 2001	435	6
	* 6,277,489	Abbott et al.	August 21, 2001	428	403
	* 6,277,581	O'Brien; et al.	August 21, 2001	435	6
	* 6,277,621	Horsburgh et al.	August 21, 2001	435	235.1
	* 6,277,628	Johann et al.	August 21, 2001	435	287.2
	* 6,294,338	Nunomura	September 25, 2001	435	
	* 6,294,331	Ried et al.	September 25, 2001	435	6
	* 6,335,167	Pinkel et al.	January 1, 2002	435	6
	* 6,365,349	Moynihan et al.	April 2, 2002	435	6
	* 6,387,626	Shi et al.	May 14, 2002	435	6
	* 6,458,584	Mirzabekov et al.	October 1, 2002	435	287.2
	* 6,503,711	Krull et al.	January 7, 2003	435	6
	* 6,516,276	Ghandour et al.	February 4, 2003	702	27
	* 6,521,465	Stimpson	February 18, 2003	436	518

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket 2004117-0024		In re Application No. 10/577,341	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				Applicant: Bianchi, <i>et al.</i>			
				Filing Date: April 28, 2006		Group: TBA	
	* 6,558,907	Koroulis et al	May 6, 2003	435	6		
	* 6,562,565	Pinkel et al.	May 13, 2003	435	6		
	* 6,576,424	Fodor et al.	June 10, 2003	435	6		
	* 6,587,579	Bass	July 1, 2003	382	141		
	* 6,589,726	Butler et al.	July 8, 2003	435	4		
	* 6,594,432	Chen et al	July 15, 2003	385	133		
	* 6,599,693	Webb	July 29, 2003	435	4		
	* 6,600,031	Fodor et al.	July 29, 2003	536	24.3		
	* 6,613,893	Webb	September 2, 2003	536	25.3		
U.S. PATENT APPLICATIONS							
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:		
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Document No.	Country	International Publication Date	Translation			
				Yes	No		
	EP 1 026 260	Europe	August 9, 2000		X		
	EP 1 134 293	Europe	September 19, 2001		X		
OTHER DOCUMENTS							
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Aljanabi and Martinez, "Universal and rapid salt-extraction of high quality genomic DNA for PCR-based techniques", <i>Nucl. Acids Res.</i> , 1997, 25 : 4692-4693.						
	Amicucci <i>et al.</i> , "Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma", <i>Clin. Chem.</i> , 2000, 46 : 301-302.						
	Belousov <i>et al.</i> , "Sequence-specific targeting and covalent modification of human genomic DNA", <i>Nucleic Acids Res.</i> , 1997, 25 : 3440-3444.						
	Bianchi <i>et al.</i> , "Detection of fetal cells with 47,XY,+21 karyotype in maternal peripheral blood", <i>Hum. Genet.</i> , 1992, 90 : 368-370.						
	Bianchi <i>et al.</i> , "Erythroid-specific antibodies enhance detection of fetal nucleated erythrocytes in maternal blood", <i>Prenatal. Diagn.</i> , 1993, 13 : 293-300.						
	Bianchi <i>et al.</i> , "PCR quantitation of fetal cells in maternal blood in normal and aneuploid						

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant:
Bianchi, *et al.*

Filing Date:
April 28, 2006

Group:
TBA

- | | |
|--|--|
| | pregnancies", <i>Am. J. Hum. Genet.</i> , 1997, 61 : 822-829. |
| | Bianchi, "Fetal DNA in maternal plasma: the placental barrier thins", <i>Am. J. Hum. Genet.</i> , 1998, 62 : 763-764. |
| | Bianchi <i>et al.</i> , "Large amounts of cell-free fetal DNA are present in amniotic fluid", <i>Clin. Chem.</i> , 2001, 47 : 1867-1869. |
| | Bianchi <i>et al.</i> , "Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study", <i>Prenat. Diagn.</i> , 2002, 22 : 609-615. |
| | Bohmer <i>et al.</i> , "Differential development of fetal and adult haemoglobin profiles in colony culture: isolation of fetal nucleated red cells by two-colour fluorescence labelling", <i>Br. J. Haematol.</i> , 1998, 103 : 351-360. |
| | Bowtell, "Options available--from start to finish--for obtaining expression data by microarray", <i>Nature Gen.</i> , 1999, Supp. 21 :25-32. |
| | Brazma and Vilo, "Gene expression data analysis", <i>FEBS Lett.</i> , 2000, 480 : 17-24. |
| | Brison <i>et al.</i> , "General method for cloning amplified DNA by differential screening with genomic probes", <i>Mol. Cell. Biol.</i> , 1982, 2 : 578-587. |
| | Bryndorf <i>et al.</i> , "Rapid prenatal diagnosis of chromosome aneuploidies by interphase fluorescence in situ hybridization: a one-year clinical experience with high-risk and urgent fetal and postnatal samples", <i>Acta Obstet. Gynecol. Scand.</i> , 2000, 79 : 8-14. |
| | Chan <i>et al.</i> , "Size distributions of maternal and fetal DNA in maternal plasma", <i>Clin. Chem.</i> , 2004, 50 : 88-92. |
| | Chen <i>et al.</i> , "Fetal DNA in maternal plasma: the prenatal detection of a paternally inherited fetal aneuploidy", <i>Prenat. Diag.</i> , 2000, 20 : 355-357 |
| | Chen <i>et al.</i> , "Fetal DNA analyzed in plasma from a mother's three consecutive pregnancies to detect paternally inherited aneuploidy", <i>Clin. Chem.</i> , 2001, 47 : 937-939. |
| | Cheung <i>et al.</i> , "Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood", <i>Nature Genet.</i> , 1996, 14 : 264-268. |
| | Cheung <i>et al.</i> , "Making and reading microarrays", <i>Nature Genet.</i> , 1999, 21 : 15-19. |
| | Daniely <i>et al.</i> , "Detection of chromosomal aberration in fetuses arising from recurrent spontaneous abortion by comparative genomic hybridization", <i>Hum. Reprod.</i> , 1998, 13 : 805-809. |
| | De la Cruz <i>et al.</i> , "Low-false positive rate of aneuploidy detection using fetal cells isolated from maternal blood", <i>Fetal Diagn. Ther.</i> , 1998, 13 : 380. |
| | DeRisi <i>et al.</i> , "Use of a cDNA microarray to analyse gene expression patterns in human cancer", <i>Nature Genet.</i> , 1996, 14 : 457-460. |
| | Di Naro <i>et al.</i> , "Prenatal diagnosis of beta-thalassaemia using fetal erythroblasts enriched from maternal blood by a novel gradient", <i>Mol. Hum. Reprod.</i> , 2000, 6 : 571-574. |

Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket 2004117-0024	In re Application No. 10/577,341
		Applicant: Bianchi, <i>et al.</i>	
		Filing Date: April 28, 2006	Group: TBA
	Divane <i>et al.</i> , "Rapid prenatal diagnosis of aneuploidy from uncultured amniotic fluid cells using five-colour fluorescence in situ hybridization", <i>Prenat. Diagn.</i> , 1994, 14 : 1061-1069.		
	du Manoir <i>et al.</i> , "Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization", <i>Hum. Genetics</i> , 1993, 90 : 590-610		
	Eisen <i>et al.</i> , "Cluster analysis and display of genome-wide expression patterns", <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95 : 14863-14868.		
	Elias <i>et al.</i> , "First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood", <i>Lancet</i> , 1992, 340 : 1033.		
	Faas <i>et al.</i> , "Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma", <i>Lancet</i> , 1998, 352 : 1196.		
	Findlay <i>et al.</i> , "Rapid trisomy diagnosis (21, 18, and 13) using fluorescent PCR and short tandem repeats: applications for prenatal diagnosis and preimplantation genetic diagnosis", <i>J. Assist. Reprod. Genet.</i> , 1998, 15 : 266-275.		
	Flint <i>et al.</i> , "The detection of subtelomeric chromosomal rearrangements in idiopathic mental retardation", <i>Nature Genet.</i> , 1995, 9 : 132-140.		
	Freeman <i>et al.</i> , "Fundamentals of DNA hybridization arrays for gene expression analysis", <i>Biotechniques</i> , 2000, 29 : 1042-1046		
	Gänshirt-Ahlert <i>et al.</i> , "Detection of fetal trisomies 21 and 18 from maternal blood using triple gradient and magnetic cell sorting", <i>Am. J. Reprod. Immunol.</i> , 1993, 30 : 193-200.		
	Gonzalez-Gonzalez <i>et al.</i> , "Prenatal detection of a cystic fibrosis mutation in fetal DNA from maternal plasma", <i>Prenatal Diagn.</i> , 2002, 22 : 946-948.		
	Guatelli <i>et al.</i> , "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication", <i>Proc. Natl. Acad. Sci. USA</i> , 1990, 87 : 1874-1878		
	Gustincich <i>et al.</i> , "A fast method for high-quality genomic DNA extraction from whole human blood", <i>BioTechniques</i> , 1991, 11 : 298-302		
	Haddad <i>et al.</i> , "Identification of de novo chromosomal markers and derivatives by spectral karyotyping", <i>Hum. Genet.</i> , 1998, 103 : 619-625.		
	Hahn <i>et al.</i> , "Multiplex and real-time quantitative PCR on fetal DNA in maternal plasma. A comparison with fetal cells isolated from maternal blood", <i>Ann. N.Y. Acad. Sci.</i> , 2000, 906 : 148-152.		
	Holmes, "Genetic counseling for the older pregnant woman: new data and questions", <i>New Eng. J. Med.</i> , 1978, 298 : 1419-1421.		
	Honda <i>et al.</i> , "Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum", <i>Hum. Genet.</i> , 2002, 110 : 75-79.		
	Jalal <i>et al.</i> , "Prenatal detection of aneuploidy by directly labeled multicolored probes and interphase fluorescence in situ hybridization", <i>Mayo Clin. Proc.</i> , 1998, 73 : 132-137.		
	Johnson <i>et al.</i> , "Interlaboratory comparison of fetal male DNA detection from common maternal		

Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket 2004117-0024	In re Application No. 10/577,341
		Applicant: Bianchi, <i>et al.</i>	
		Filing Date: April 28, 2006	Group: TBA
	plasma samples by real-time PCR”, <i>Clin. Chem.</i> , 2004, 50 : 516-521.		
	Joos <i>et al.</i> , “Mapping and chromosome analysis: the potential of fluorescence in situ hybridization”, <i>J. Biotechnol.</i> , 1994, 35 : 135-153.		
	Kallioniemi <i>et al.</i> , “Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors”, <i>Science</i> , 1992, 258 : 818-821.		
	Kallioniemi <i>et al.</i> , “Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors”, <i>Semin. Cancer Biol.</i> , 1993, 4 : 41-46.		
	Kerr <i>et al.</i> , “Analysis of variance for gene expression microarray data”, <i>J. Comput. Biol.</i> , 2000, 7 : 819-837.		
	Knight <i>et al.</i> , “Subtle chromosomal rearrangements in children with unexplained mental retardation”, <i>Lancet</i> , 1999, 354 : 1676-1681.		
	Lapaire <i>et al.</i> , “Larger columns and change of lysis buffer increase the yield of cell-free DNA extracted from amniotic fluid”, <i>Clin. Chem.</i> , 2006, 52 : 156-157.		
	Larrabee <i>et al.</i> , “Microarray analysis of cell-free fetal DNA in amniotic fluid: a prenatal molecular karyotype”, <i>Am. J. Hum. Genet.</i> , 2004, 75 : 485-491.		
	Larrabee <i>et al.</i> , “Presence of filterable and nonfilterable cell-free mRNA in amniotic fluid”, <i>Clin. Chem.</i> , 2005, 51 : 1024-1026.		
	Lee <i>et al.</i> , “Down syndrome and cell-free fetal DNA in archived maternal serum”, <i>Am. J. Obstet. Gynecol.</i> , 2002, 187 : 1217-1221.		
	Leung <i>et al.</i> , “Maternal plasma fetal DNA as a marker for preterm labour”, <i>Lancet</i> , 1998, 352 : 1904-1905.		
	Lo <i>et al.</i> , “Presence of fetal DNA in maternal plasma and serum”, <i>Lancet</i> , 1997, 350 : 485-487.		
	Lo <i>et al.</i> , “Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis”, <i>Am. J. Hum. Genet.</i> , 1998, 62 : 768-775.		
	Lo <i>et al.</i> , “Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma”, <i>New Engl. J. Med.</i> , 1998, 339 : 1734-1738.		
	Lo <i>et al.</i> , “Rapid clearance of fetal DNA from maternal plasma”, <i>Am. J. Hum. Genet.</i> , 1999, 64 : 218-224.		
	Lo <i>et al.</i> , “Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21”, <i>Clin. Chem.</i> , 1999, 45 : 1747-1751.		
	Lo <i>et al.</i> , “Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia”, <i>Clin. Med.</i> , 1999, 45 : 184-188.		
	Lo <i>et al.</i> , “Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21”, <i>Clin. Med.</i> , 1999, 45 : 1747-1751.		
	Lucotte <i>et al.</i> , “Nucleotide sequence of p49a, a genomic Y-specific probe with potential utilization in sex determination.”, <i>Mol. Cell. Probes</i> , 1991, 5 : 359-363.		

Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce	Attorney Docket	In re Application No.
	Patent and Trademark Office	2004117-0024	10/577,341
	Applicant: Bianchi, <i>et al.</i>		
		Filing Date: April 28, 2006	Group: TBA

	Mei <i>et al.</i> , "Genome-wide detection of allelic imbalance using human SNPs and high density DNA arrays", <i>Genome Res.</i> , 2000, 10 : 1126-1137.
	Moore <i>et al.</i> , "Examination of trisomy 13, 18 and 21 foetal tissues at different gestational ages using FISH", <i>Eur. J. Hum. Genet.</i> , 2000, 8 : 223-228
	Ordahl <i>et al.</i> , "Sheared DNA fragment sizing: comparison of techniques", <i>Nucleic Acids Res.</i> , 1976, 3 : 2985-2999.
	Parano <i>et al.</i> , "Noninvasive prenatal diagnosis of chromosomal aneuploidies by isolation and analysis of fetal cells from maternal blood", <i>Am. J. Med. Genet.</i> , 2001, 101 : 262-267.
	Pergament <i>et al.</i> , "The clinical application of interphase FISH in prenatal diagnosis", <i>Prenatal. Diagn.</i> , 2000, 20 : 215-230.
	Pertl and Bianchi, "Fetal DNA in maternal plasma: emerging clinical applications", <i>Obstet. Gynecol.</i> , 2001, 98 : 483-490.
	Peschka <i>et al.</i> , "Analysis of a de novo complex chromosome rearrangement involving chromosomes 4, 11, 12 and 13 and eight breakpoints by conventional cytogenetic, fluorescence in situ hybridization and spectral karyotyping", <i>Prenatal. Diagn.</i> , 1999, 19 : 1143-1149.
	Pinkel <i>et al.</i> , "High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays", <i>Nature Genet.</i> , 1998, 20 : 207-211.
	Pollack <i>et al.</i> , "Genome-wide analysis of DNA copy-number changes using cDNA microarrays", <i>Nature Genet.</i> , 1999, 23 : 41-46.
	Poon <i>et al.</i> , "Prenatal detection of fetal Down's syndrome from maternal plasma", <i>Lancet</i> , 2000, 356 : 1819-1820.
	Rosenfeld, "Human artificial chromosomes get real", <i>Nature Genet.</i> , 1997, 15 : 333-335.
	Roush, "Counterfeit chromosomes for humans", <i>Science</i> , 1997, 276 : 38-39
	Saccone <i>et al.</i> , "The highest gene concentrations in the human genome are in telomeric bands of metaphase chromosomes", <i>Proc. Natl. Acad. Sci. USA</i> , 1992, 89 : 4913-4917.
	Saito <i>et al.</i> , "Prenatal DNA diagnosis of a single-gene disorder from maternal plasma", <i>Lancet</i> , 2000, 356 : 1170.
	Schena <i>et al.</i> , "Parallel human genome analysis: microarray-based expression monitoring of 1000 genes", <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93 : 10614-10619.
	Schrock <i>et al.</i> , "Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities", <i>Hum. Genet.</i> , 1997, 101 : 255-262.
	Simpson and Elias, "Isolating fetal cells from maternal blood. Advances in prenatal diagnosis through molecular technology", <i>J. Am. Med. Assoc.</i> , 1993, 270 : 2357-2361.
	Solinas-Toldo <i>et al.</i> , "Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances", <i>Genes, Chromosomes & Cancer</i> , 1997, 20 : 399-407.
	Thein <i>et al.</i> , "An assessment of the use of interphase FISH with chromosome specific probes as an

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket 2004117-0024	In re Application No. 10/577,341
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				Applicant: Bianchi, <i>et al.</i>	
				Filing Date: April 28, 2006	
				Group: TBA	
	alternative to cytogenetics in prenatal diagnosis", <i>Prenat. Diagn.</i> , 2000, 20 : 275-280.				
	Van den Veyver and B.B. Roa, "Applied molecular genetic techniques for prenatal diagnosis", <i>Curr. Opin. Obstet. Gynecol.</i> , 1998, 10 : 97-103.				
	Wakui <i>et al.</i> , "Clinical applications of two-color telomeric fluorescence in situ hybridization for prenatal diagnosis: identification of chromosomal translocation in five families with recurrent miscarriages or a child with multiple congenital anomalies", <i>J. Hum. Genet.</i> , 1999, 44 : 85-90.				
	Weremowicz <i>et al.</i> , "Fluorescence in situ hybridization (FISH) for rapid detection of aneuploidy: experience in 911 prenatal cases", <i>Prenat. Diagn.</i> , 2001, 21 : 262-269.				
	Zhong <i>et al.</i> , "Detection of fetal Rhesus D and sex using fetal DNA from maternal plasma by multiplex polymerase chain reaction", <i>Brit. J. Obstet. Gynaecol.</i> , 2000, 107 : 766-769.				
	Zhong <i>et al.</i> , "Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses", <i>Prenatal Diagn.</i> , 2000, 20 : 795-798.				
	Zhong <i>et al.</i> , "Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia", <i>Ann. N.Y. Acad. Sci.</i> , 2001, 945 : 138-140.				
	Zheng <i>et al.</i> , "Prenatal diagnosis from maternal blood: simultaneous immunophenotyping and FISH of fetal nucleated erythrocytes isolated by negative magnetic cell sorting", <i>J. Med. Genet.</i> , 1993, 30 : 1051-1056.				
EXAMINER				DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					